Clinical overview of trophoblast surface antigen 2 antibody-drug conjugates in non–small cell lung cancer
Cancer Treatment Reviews · 2026-02 · 143 · 103050
DOI: 10.1016/j.ctrv.2025.103050 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Treatment Reviews, 2026-02. Verfasst von Sandip Pravin Patel und 4 weiteren Autor:innen. Beteiligte Einrichtung: University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immunoconjugates, Cell Adhesion Molecules. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Daiichi-Sankyo.
Abstract (Originalsprache)
Lung cancer remains the leading cause of cancer-related death in the United States, with non-small cell lung cancer (NSCLC) accounting for most lung cancer cases. Improvements in first-line treatment with immuno-oncology and targeted therapies have been observed in patients with NSCLC, but benefits may be limited for those with advanced or metastatic NSCLC (mNSCLC). Following progression on frontline therapies, later-line therapies offer modest benefits and are associated with pronounced adverse effects. Accordingly, there is a need for new, more effective options to improve survival and quality of life. Trophoblast surface antigen 2 (TROP2) antibody-drug conjugates (ADCs) are a novel approach to address unmet treatment needs in NSCLC. There are 5 TROP2-directed ADCs currently under investigation for treatment of NSCLC: datopotamab deruxtecan, sacituzumab govitecan, sacituzumab tirumotecan, DB-1305, and SHR-A1921. Here, we provide an overview of the properties of each ADC as well as efficacy and safety data from clinical trials of patients with NSCLC with or without actionable genomic alterations (AGAs). The unique characteristics of each ADC and its components, particularly the linker chemistry and payload attributes, define the mechanism of action and subsequently influence dosing, efficacy, and safety. TROP2 ADCs have shown antitumor responses with a manageable safety profile in patients with mNSCLC in several ongoing and completed trials. Additional studies are required to understand how these agents can be effectively integrated into the treatment paradigm for lung cancer, taking into consideration sequential use of multiple ADCs, resistance mechanisms, combination therapies, and use in special populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.
- Henry Ford Health, One Ford Place, Detroit, MI 48202, USA.
- Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114, USA.
- Johns Hopkins University, 1800 Orleans Street, Baltimore, MD 21287, USA.
- Loyola University Chicago, 2160 South First Avenue, Maywood, IL 60153, USA.
Förderung
- Daiichi-Sankyo
Zitieren
APA
Patel, S. P., Gadgeel, S., Mino-Kenudson, M., Naidoo, J., & Sethakorn, N. (2026). Clinical overview of trophoblast surface antigen 2 antibody-drug conjugates in non–small cell lung cancer. Cancer Treatment Reviews, 143, 103050. https://doi.org/10.1016/j.ctrv.2025.103050
Vancouver
Patel SP, Gadgeel S, Mino-Kenudson M, Naidoo J, Sethakorn N. Clinical overview of trophoblast surface antigen 2 antibody-drug conjugates in non–small cell lung cancer. Cancer Treatment Reviews. 2026;143:103050. doi:10.1016/j.ctrv.2025.103050
BibTeX
@article{Patel2026,
author = {Patel, Sandip Pravin and Gadgeel, Shirish and Mino-Kenudson, Mari and Naidoo, Jarushka and Sethakorn, Nan},
title = {Clinical overview of trophoblast surface antigen 2 antibody-drug conjugates in non–small cell lung cancer},
journal = {Cancer Treatment Reviews},
year = {2026},
volume = {143},
pages = {103050},
doi = {10.1016/j.ctrv.2025.103050}
}
EUVIMED